We then examined the therapeutic effect of anti-CXCL16 or goat IgG isotype control (IgG) in the BCR-ABL-induced B-ALL secondary transplantation mouse model (Fig. 7i). This evidence concerns the gene ABL1 and precursor B-cell acute lymphoblastic leukemia.